224 related articles for article (PubMed ID: 33038328)
21. Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
Mohd Siddique MU; Thakur A; Shilkar D; Yasmin S; Halakova D; Kovacikova L; Prnova MS; Stefek M; Acevedo O; Dasararaju G; Devadasan V; Mondal SK; Jayaprakash V
Eur J Med Chem; 2021 Nov; 223():113630. PubMed ID: 34175538
[TBL] [Abstract][Full Text] [Related]
22. Enhancing activity and selectivity in a series of pyrrol-1-yl-1-hydroxypyrazole-based aldose reductase inhibitors: The case of trifluoroacetylation.
Papastavrou N; Chatzopoulou M; Ballekova J; Cappiello M; Moschini R; Balestri F; Patsilinakos A; Ragno R; Stefek M; Nicolaou I
Eur J Med Chem; 2017 Apr; 130():328-335. PubMed ID: 28259841
[TBL] [Abstract][Full Text] [Related]
23. Novel substituted N-benzyl(oxotriazinoindole) inhibitors of aldose reductase exploiting ALR2 unoccupied interactive pocket.
Hlaváč M; Kováčiková L; Šoltésová Prnová M; Addová G; Hanquet G; Štefek M; Boháč A
Bioorg Med Chem; 2021 Jan; 29():115885. PubMed ID: 33271452
[TBL] [Abstract][Full Text] [Related]
24. 1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors.
Papastavrou N; Chatzopoulou M; Pegklidou K; Nicolaou I
Bioorg Med Chem; 2013 Sep; 21(17):4951-7. PubMed ID: 23891165
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, molecular modeling, selective aldose reductase inhibition and hypoglycemic activity of novel meglitinides.
Salem MG; Abdel Aziz YM; Elewa M; Nafie MS; Elshihawy HA; Said MM
Bioorg Chem; 2021 Jun; 111():104909. PubMed ID: 33895603
[TBL] [Abstract][Full Text] [Related]
26. Development of Novel Oxotriazinoindole Inhibitors of Aldose Reductase: Isosteric Sulfur/Oxygen Replacement in the Thioxotriazinoindole Cemtirestat Markedly Improved Inhibition Selectivity.
Hlaváč M; Kováčiková L; Prnová MŠ; Šramel P; Addová G; Májeková M; Hanquet G; Boháč A; Štefek M
J Med Chem; 2020 Jan; 63(1):369-381. PubMed ID: 31820975
[TBL] [Abstract][Full Text] [Related]
27. Substituted 2-thioxothiazolidin-4-one derivatives showed protective effects against diabetic cataract via inhibition of aldose reductase.
Huang W; Zhang Y; Liang X; Yang L
Arch Pharm (Weinheim); 2020 Jun; 353(6):e1900371. PubMed ID: 32237167
[TBL] [Abstract][Full Text] [Related]
28. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Hotta N; Kawamori R; Fukuda M; Shigeta Y;
Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, activity, and molecular modeling of new 2, 4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors.
Fresneau P; Cussac M; Morand JM; Szymonski B; Tranqui D; Leclerc G
J Med Chem; 1998 Nov; 41(24):4706-15. PubMed ID: 9822541
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of [1,2,4]triazino[4,3-a] benzimidazole acetic acid derivatives as selective aldose reductase inhibitors.
Sahoo PK; Behera P
Eur J Med Chem; 2010 Mar; 45(3):909-14. PubMed ID: 19962793
[TBL] [Abstract][Full Text] [Related]
31. Virtual screening of epalrestat mimicking selective ALR2 inhibitors from natural product database: auto pharmacophore, ADMET prediction and molecular dynamics approach.
Choudhary S; Silakari O
J Biomol Struct Dyn; 2022 Aug; 40(13):6052-6070. PubMed ID: 33480327
[TBL] [Abstract][Full Text] [Related]
32. In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors.
Maccari R; Del Corso A; Giglio M; Moschini R; Mura U; Ottanà R
Bioorg Med Chem Lett; 2011 Jan; 21(1):200-3. PubMed ID: 21129963
[TBL] [Abstract][Full Text] [Related]
33. Novel quinazolinone-based 2,4-thiazolidinedione-3-acetic acid derivatives as potent aldose reductase inhibitors.
Metwally K; Pratsinis H; Kletsas D; Quattrini L; Coviello V; Motta C; El-Rashedy AA; Soliman ME
Future Med Chem; 2017 Dec; 9(18):2147-2166. PubMed ID: 29098865
[TBL] [Abstract][Full Text] [Related]
34. Effects of a new aldose reductase inhibitor on various tissues in vitro.
Terashima H; Hama K; Yamamoto R; Tsuboshima M; Kikkawa R; Hatanaka I; Shigeta Y
J Pharmacol Exp Ther; 1984 Apr; 229(1):226-30. PubMed ID: 6423811
[TBL] [Abstract][Full Text] [Related]
35. Dihydrobenzoxazinone derivatives as aldose reductase inhibitors with antioxidant activity.
Chen H; Zhang X; Zhang X; Fan Z; Liu W; Lei Y; Zhu C; Ma B
Bioorg Med Chem; 2020 Oct; 28(20):115699. PubMed ID: 33069078
[TBL] [Abstract][Full Text] [Related]
36. 1,2-Benzothiazine 1,1-dioxide carboxylate derivatives as novel potent inhibitors of aldose reductase.
Chen X; Zhang S; Yang Y; Hussain S; He M; Gui D; Ma B; Jing C; Qiao Z; Zhu C; Yu Q
Bioorg Med Chem; 2011 Dec; 19(23):7262-9. PubMed ID: 22036211
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of aldehyde reductase by aldose reductase inhibitors.
Sato S; Kador PF
Biochem Pharmacol; 1990 Sep; 40(5):1033-42. PubMed ID: 2117925
[TBL] [Abstract][Full Text] [Related]
38. Thienocinnolinone alkanoic acid derivatives as aldose reductase inhibitors.
Pau A; Asproni B; Murineddu G; Boatto G; Grella GE; Rakowitz D; Costantino L; Pinna GA
Med Chem; 2006 Jan; 2(1):39-45. PubMed ID: 16787354
[TBL] [Abstract][Full Text] [Related]
39. Aldose reductase structures: implications for mechanism and inhibition.
El-Kabbani O; Ruiz F; Darmanin C; Chung RP
Cell Mol Life Sci; 2004 Apr; 61(7-8):750-62. PubMed ID: 15095000
[TBL] [Abstract][Full Text] [Related]
40. Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells.
Ishibashi Y; Matsui T; Matsumoto T; Kato H; Yamagishi S
Diab Vasc Dis Res; 2016 Jul; 13(4):312-5. PubMed ID: 27190083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
